Acutus Medical, Inc. (ACM), a medical device company developing a minimally invasive real-time 3D Cardiac Chamber Imaging and Dipole Density Mapping system to identify the sources that cause and / or sustain complex cardiac arrhythmias, including atrial fibrillation, announced it has completed an additional $26.2M financing to continue developing its imaging/mapping system as well as bring to market a complete product portfolio.
The financing will allow Acutus Medical to complete work on the AcQMapTM High Resolution, Imaging and Mapping System and broaden their product portfolio to include diagnostic catheters, therapeutic catheters and additional new innovative therapeutic products. Acutus Medical will also be collaborating with Boise State University to develop a next generation therapeutic technology. The expansion of the portfolio to include everything needed to diagnose and treat all EP patients puts Acutus Medical in a position to be a complete, stand-alone business.
"We are pleased to be working with top tier investors that share our passion to develop the AcQMap System but understand the importance of offering a complete portfolio of products to help physicians tailor patient treatment while being respectful of the financial pressure on healthcare systems worldwide," Randy Werneth, President and Chief Executive Officer stated. "Completion of this round of financing provides us with the opportunity to expand our product portfolio in many ways and continue to innovate and validate our core product, the AcQMap System."
New genetic insights: Sugary beverages linked to higher risk of atrial fibrillation